Plasma levels of salmeterol, a component of Fluticasone Propionate and Salmeterol Inhalation Powder, after inhaled therapeutic doses are very low. In rats, salmeterol xinafoate is excreted in the milk. There are no data from controlled trials on the use of salmeterol by nursing mothers. It is not known whether fluticasone propionate, a component of Fluticasone Propionate and Salmeterol Inhalation Powder, is excreted in human breast milk. However, other corticosteroids have been detected in human milk. Subcutaneous administration to lactating rats of tritiated fluticasone propionate resulted in measurable radioactivity in milk.
In rabbits, fetal weight reduction and cleft palate were observed at a fluticasone propionate dose approximately times the MRHDID for adults (on a mg/m² basis at a maternal subcutaneous dose of 4 mcg/kg/day). However, no teratogenic effects were reported at fluticasone propionate doses up to approximately 20 times the MRHDID for adults (on a mg/m² basis at a maternal oral dose up to 300 mcg/kg/day). No fluticasone propionate was detected in the plasma in this study, consistent with the established low bioavailability following oral administration [see CLINICAL PHARMACOLOGY ].
(A) Body weight of three-month-old Ffar3 knockouts and wild-type littermates on standard chow diet and one week after switching to HFD. N=34–41. (B-D) After one week of HFD feeding, Ffar3 knockouts and wild-type littermates were switched to HFD containing sodium butyrate (5%) or sodium propionate (%) for eight days. Cumulative body weight change and daily food intake are shown. Data are mean ± SEM. N=8–13. *P<, **P<, ***P< vs. control diet. #P< vs. wild-type mice on control diet. NS: not significant.